ALXN2220-ATTR-CM-301
Recruiting
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
This is a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of amyloid depleter ALXN2220 compared to placebo in adult participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).Approximately 1000 participants will be enrolled and randomized to receive either ALXN2220 or placebo in a 2:1 ratio. Participants will receive study intervention (ALXN2220 or placebo) q4w via IV infusion for at least 24 months up to a maximum of 48 months.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
12 Sep 2024.
Study ID: 854884
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
